Search

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.

… Wednesday, January 17, 2018 Summary A new finding suggests that a genetic mistake in cancer cells known as chromosomal instability creates an inflammatory state within the cells. The cancer cells take advantage of this condition by hijacking pathways used by immune cells to migrate. This enables these

Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.

… Thursday, December 5, 2013 Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute , Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center that is designed to

The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.

… Monday, May 12, 2025 The first drug for a rare and difficult-to-treat type of  ovarian cancer has been granted  accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki TM Fakzynja TM Co-pack), was developed to treat low-grade serous

Learn about how The Society of Memorial Sloan Kettering is supporting precision medicine at MSK Kids.

… Wednesday, April 1, 2020 On February 5, The Society of Memorial Sloan Kettering hosted its seventh annual Winter Lunch to support its Precision Medicine for MSK Kids initiative. More than 275 guests attended this year’s event, which was sponsored by Net-a-Porter for the fifth consecutive year, at the

Androgen deprivation therapy may depress testosterone for prolonged periods in older patients, or those who are on the treatment for more than six months, increasing the risk of associated adverse events, according to the results of our recent retrospective study.

… Tuesday, October 8, 2019 Despite the intention to reduce testosterone temporarily, androgen deprivation therapy (ADT) may lower it for prolonged periods in patients over the age of 65 or those who take ADT for more than six months, according to the results of our recent retrospective study. Given the

An MSK clinical trial is helping Gail Goode overcome multiple myeloma and sheds new light on how cancer affects people of diverse ethnic backgrounds.

… Tuesday, September 3, 2024 There is an urgent need to recruit more diverse patients into cancer clinical trials . One reason it’s so important is that researchers are learning that certain types of cancer occur more frequently in people with certain ancestries. For example:   African — people of African

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

… Wednesday, June 26, 2019 Summary Researchers at Memorial Sloan Kettering have identified molecular changes in a protein that promote a distinct type of prostate cancer. The findings suggest that this protein could be a good drug target for men with this form of the disease. Prostate cancer is not one

Antibody-drug conjugates and checkpoint inhibitors show promise as new therapies for bladder cancer.

… Monday, September 12, 2022 Promising new drugs have begun to transform the treatment of bladder (or urothelial) cancer, the sixth most common form of the disease in the U.S., and the fourth most common in men. In particular, two drug classes, antibody-drug conjugates (ADCs) and checkpoint inhibitors,

Tune in to today’s “MSK Science Spotlight.” The April 20 lecture, “A Single Cell Lens into the Roles of Cellular Plasticity in Development and Cancer,” will feature Dana Pe’er, PhD.

… Monday, April 20, 2020 Tune in to today’s “ MSK Science Spotlight .” The Sloan Kettering Institute’s online seminar series for the scientific community features illuminating lectures by today’s leaders in basic and translational biomedical science and reminds us all that the fight against cancer must

Three second-year students -- Neha Bhagwat, John Halliday, and Ellen Hukkelhoven -- received Geoffrey Beene Graduate Student Fellowships.

… Thursday, October 1, 2009 Three second-year students — Neha Bhagwat, John Halliday, and Ellen Hukkelhoven — received Geoffrey Beene Graduate Student Fellowships. These fellowships were awarded by the Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer Center, which was established